Vivani Medical Inc. (VANI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vivani Medical Inc. (VANI) has a cash flow conversion efficiency ratio of -0.427x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.72 Million) by net assets ($15.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VANI equity financing ratio to measure how much of total assets are equity-financed.
Vivani Medical Inc. - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Vivani Medical Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vivani Medical Inc. earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Vivani Medical Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivani Medical Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Social Commerce Partners Corporation Class A Ordinary Shares
NASDAQ:SCPQ
|
N/A |
|
NeoPharm CO. LTD
KQ:092730
|
0.031x |
|
Synchronoss Technologies Inc
NASDAQ:SNCR
|
0.711x |
|
Havila Kystruten AS
OL:HKY
|
-0.034x |
|
Xtract One Technologies Inc.
TO:XTRA
|
-0.220x |
|
SA Catana Group
PA:CATG
|
0.120x |
|
G J Steel Public Company Limited
BK:GJS
|
0.051x |
|
Dongyang E&P Inc
KQ:079960
|
0.049x |
Annual Cash Flow Conversion Efficiency for Vivani Medical Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of Vivani Medical Inc. from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Vivani Medical Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.73 Million | $-24.32 Million | -1.546x | -30.99% |
| 2024-12-31 | $17.61 Million | $-20.79 Million | -1.180x | -3.40% |
| 2023-12-31 | $20.76 Million | $-23.70 Million | -1.142x | -169.22% |
| 2022-12-31 | $44.31 Million | $-18.79 Million | -0.424x | +90.46% |
| 2021-12-31 | $2.46 Million | $-10.95 Million | -4.443x | -13.70% |
| 2020-12-31 | $1.95 Million | $-7.62 Million | -3.907x | -2.88% |
| 2019-12-31 | $7.28 Million | $-27.63 Million | -3.798x | +60.71% |
| 2018-12-31 | $3.08 Million | $-29.81 Million | -9.666x | -218.15% |
| 2017-12-31 | $7.88 Million | $-23.95 Million | -3.038x | -35.12% |
| 2016-12-31 | $11.15 Million | $-25.07 Million | -2.248x | -121.77% |
| 2015-12-31 | $20.27 Million | $-20.55 Million | -1.014x | -105.34% |
| 2014-12-31 | $34.62 Million | $-17.09 Million | -0.494x | -126.13% |
| 2013-12-31 | $-9.22 Million | $-17.43 Million | 1.890x | -62.45% |
| 2012-12-31 | $-3.04 Million | $-15.32 Million | 5.034x | -- |
About Vivani Medical Inc.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more